Just Download CAT-200 free pdf and Practice real questions

Are you searching for CA-Technologies CAT-200 dumps questions of real queries for the CA Service Desk Manager r12 Administrator Examination prep? We offer valid, most up-to-date, and quality CAT-200 braindumps. The detail will be at http://killexams.com/pass4sure/exam-detail/CAT-200. We have put together a database associated with CAT-200 braindumps from actual examinations to be able to let a person memorize and complete CAT-200 test around the 1st attempt. Just remember our Questions plus Answers and unwind. You will complete the CAT-200 exam.

Exam Code: CAT-200 Practice exam 2022 by Killexams.com team
CA Service Desk Manager r12 Administrator
CA-Technologies Administrator information
Killexams : CA-Technologies Administrator information - BingNews https://killexams.com/pass4sure/exam-detail/CAT-200 Search results Killexams : CA-Technologies Administrator information - BingNews https://killexams.com/pass4sure/exam-detail/CAT-200 https://killexams.com/exam_list/CA-Technologies Killexams : GovCon Wire

Dedrone has named Ben Wenger, a two-decade enterprise software sales veteran, as chief revenue officer and appointed Mary-Lou Smulders, strategic

Michael Barnes, former senior strategic account executive for the Department of Agriculture at Salesforce (NYSE: CRM), has joined Google's (Nasdaq:…

Mark Fabian, former strategic account executive at CA Technologies' federal business, has joined The Ambit Group as vice president of growth,…

Fri, 18 Nov 2022 10:00:00 -0600 en-US text/html https://www.govconwire.com/tag/ca-technologies/
Killexams : 2022 Council Briefing: Technology & Cybersecurity Standardization

The City of Toronto offers multiple services over the internet and is expanding its technology landscape to residents, businesses, and visitors. The City’s Technology Services Division (TSD), and Office of Chief Information Security Officer (OCISO) are enhancing cybersecurity and implementing a standardized approach for the design and delivery of information technology (IT) solutions to provide enhanced and secure experiences for residents, businesses, visitors, and City staff.

Current Status

The approach will first focus on standardizing processes and applications within City divisions, before extending to agencies and corporations.

The following steps have been taken:

  • Standardized TSD Service Intake process for City-wide requests
  • Established a TSD Enterprise Architecture Review Board for proposed technology solutions
  • The OCISO has developed Cybersecurity Governance framework for City divisions, agencies, and corporations and is working with stakeholders to ensure standardized cyber security metrics

More changes are planned, such as:

  • Standardization of City IT policies and procedures
  • Standardization of IT roles and responsibilities across Divisional IT teams
  • Operationalization of the Cyber Security Governance Framework, with focus on critical infrastructure divisions with Operational technology (OT) systems
  • Preparation and maintenance of application inventory

Background & Context

Cyberattacks can have devastating effects, resulting in an inability to deliver critical services, stolen personal data, financial losses, risk of legal lawsuits and reputational damage. To Strengthen cybersecurity considerably, the City must change in three key areas:

  1. Human Behaviour (as it relates to cybersecurity threats);
  2. Technical Fixes; and
  3. Culture Shift.

In 2019, City Council adopted AU4.1: Cyber Safety: A Robust Cybersecurity Program Needed to Mitigate Current and Emerging Threats. City Council directed the Chief Technology Officer to take an expanded City-wide role and mandate to provide support, oversight and direction on standards, practices and policies to all City Divisions and certain agencies and corporations. The City has rolled out mandatory cyber security awareness training to help City staff recognize and report cyber threats and learn how to safely use the City’s IT systems and assets. In addition, the City has implemented enhanced password rules and will continue to proactively run vulnerability assessments, penetration testing and threat risk assessment services to identify and manage cyber risks. TSD conducted Disaster Recovery (DR) activities to assess current gaps and standardize DR services.

TSD and the OCISO meet with select City agencies and corporations to discuss best practices relating to technology and cyber security standardization.

Equity, Diversity & Inclusion

The use of data and technology has equity implications predominantly associated with:

  • lack of access to the internet and internet-enabled devices (referred to as the digital divide);
  • not fully understanding and/or addressing users’ accessibility needs; and
  • the potential for automated decisions and processes to perpetuate bias and discrimination.

Technology and Cybersecurity Standardization is aligned with the City’s Digital Infrastructure Strategic Framework (DISF), which establishes guidelines that foster digital inclusion and integrates digital equity considerations into the decision-making process. The DISF includes an Equity and Inclusion Principle, supports the City of Toronto Data for Equity Strategy, and directs the City to use Digital Infrastructure to create and sustain equity and inclusion.

Key Contact

Renee Laforet
Interim Chief Technology Officer
Renee.Laforet@toronto.ca, 416-397-0500

Abiodun Morolari
Chief Information Security Officer
Abiodun.Morolari@toronto.ca, 416-396-4693

Mon, 14 Nov 2022 11:23:00 -0600 en-CA text/html https://www.toronto.ca/city-government/accountability-operations-customer-service/city-administration/for-your-information-toronto/2022-start-of-council-term-briefing/2022-council-briefing-technology-cybersecurity-standardization/
Killexams : SPX Technologies Announces Appointment of Mark Carano as Chief Financial Officer

SPX Technologies

CHARLOTTE, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SPX Technologies, Inc. (“SPX Technologies,” or “SPX”) (NYSE:SPXC) today announced the appointment of Mark A. Carano as Vice President, Chief Financial Officer and Treasurer, effective January 3, 2023. Mr. Carano joins SPX Technologies with extensive executive experience in finance, accounting, strategy, and business development, including senior leadership roles in public companies.

Gene Lowe, President and CEO, commented, “We are very pleased to welcome Mark to the SPX Technologies team. His impressive track record as a public-company CFO, and his strong background in engineered products and growth investments are an excellent fit with SPX’s growth and operational excellence initiatives. His depth of experience in strategy, finance, and business development helps position SPX for further success as we continue to pursue our value creation roadmap.”

Mr. Carano joins SPX from Insteel Industries, Inc, a publicly-traded manufacturer of steel wire reinforcing products for concrete construction applications (NYSE: IIIN), where he served as Senior Vice President, Chief Financial Officer and Treasurer. Before joining Insteel, he served as Chief Financial Officer of Big River Steel LLC, a private equity-owned manufacturer of steel products, from 2019 until its sale to U.S. Steel in 2020. Prior to Big River Steel, Mr. Carano served in senior management roles with Babcock & Wilcox, a publicly-held manufacturer of industrial technology, from 2013 to 2018, including Senior Vice President, Finance and Controller of their Industrial Segment and Senior Vice President, Corporate Development and Treasurer.

Mr. Carano also spent 14 years in investment banking, serving in roles of increasing seniority at First Union Securities, Deutsche Bank, Merrill Lynch, and BofA Merrill Lynch. He earned a bachelor’s of arts degree from Vanderbilt University and a master's degree in business administration from Northwestern University's Kellogg Business School.

About SPX Technologies: SPX Technologies is a diversified, global supplier of highly engineered products and technologies, holding leadership positions in the HVAC and detection and measurement markets. Based in Charlotte, North Carolina, SPX Technologies has more than 3,100 employees in 15 countries. SPX Technologies is listed on the New York Stock Exchange under the ticker symbol “SPXC.” For more information, please visit www.spx.com.

Investor and Media Contacts:
Paul Clegg, VP, Investor Relations and Communications
Garrett Roelofs, Assistant Manager, Investor Relations
Phone:   980-474-3806
E-mail: spx.investor@spx.com

Source: SPX Technologies, Inc.

Wed, 07 Dec 2022 07:07:00 -0600 en-CA text/html https://ca.finance.yahoo.com/news/spx-technologies-announces-appointment-mark-210600382.html
Killexams : 2022-2023 Best Colleges in California No result found, try new keyword!The California Institute of Technology focuses on science and engineering education and has a low student-to-faculty ratio of 3:1. This private institution in Pasadena, California, is actively ... Mon, 05 Dec 2022 00:22:00 -0600 text/html https://www.usnews.com/best-colleges/ca Killexams : Modular Medical Announces Product Testing Update

SAN DIEGO, CA / ACCESSWIRE / November 28, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product.

The Company has continued to make progress on the testing required for its 510(k) submission to the U.S. Food and Drug Administration ("FDA") of its MODD1 insulin pump product. The Company has identified certain material in the pump device that was incompatible with the sterilization process utilized. As previously announced, this compatibility issue has delayed the Company's 510(k) submission timeline. The Company has identified replacement materials, which are being qualified for use in the product. Given the expected resolution of the compatibility issue, the Company now expects to make its submission to the FDA during the quarter ended June 30, 2023.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause real results to be materially different from the forward-looking statement. These factors include, but are not limited to, the risk that the Company is unable to make the FDA submission in a timely manner or at all; the Company's expected resolution of its materials/sterilization compatibility issue; the Company's ability to develop production manufacturing capability; whether the Company can successfully develop the Company's proprietary technologies and whether the market will accept the Company's products and services, as well as other risk factors and business considerations described in the Company's SEC filings, including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to update these forward-looking statements, except as required by law.

About Modular Medical, Inc.

Modular Medical, Inc. (NASDAQ:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to Strengthen access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

All trademarks mentioned herein are the property of their respective owners.


Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741

SOURCE: Modular Medical, Inc.

View source version on accesswire.com:

Mon, 28 Nov 2022 00:30:00 -0600 en-US text/html https://www.yahoo.com/now/modular-medical-announces-product-testing-142900320.html

VANCOUVER, BC, Nov. 29, 2022 /CNW/ - Principal Technologies Inc. (the "Company") (TSXV: PTEC.P), which is building a diverse portfolio of investments in healthcare technologies companies, is pleased to provide this corporate update to shareholders.

The Company is pleased to announce that it has initiated proceedings of a potential $500,000 private placement financing that will be finalized as soon as the delayed financial filings are delivered, which is expected by December 15, 2022 or earlier, and the CTO is removed. The funds will be used in parts to secure options for participations in targets that will increase the intrinsic value of the company. Details about the financing will follow in due course.

The company is also pleased to announce it has expanded its advisory board by adding high profile individuals from the fields of business & finance as well as technology.

Dr. Gerald (Geri) Rainer, former CEO of one of the largest Swiss Private Banks and trustee on several international multi billion dollar trusts (among other experience), and Dr. Ivo Ivanovski, former Information Technology Minister of the Republic of Macedonia.

Besides from Dr. Rainer's business acumen and his generally extensive international network, the Company expects benefitting in particular from his institutional investor contacts and their financial backing of larger transactions and participations we plan on conducting in the new year.

Dr. Ivanovski, who is currently among others member of the Advisory Committee of the prestigious World Information Technology and Services Alliance (WITSA), will be instrumental in the appraisal of international technology trends, especially with regard to cloud-related healthcare technologies solutions for hospitals where large telecommunication companies hold strong footholds.

His Serene Highness Prince Alfred of Liechtenstein, Chairman of the Board of Directors (the "Board"), as well as the rest of the Board, warmly welcome Geri and Ivo to the company. Dr. Rainer, will serve as Chairman of the Advisory Board.

In the meantime, the Company's portfolio companies, E&E CRO Consulting and Vision Surgery AI (VSAI), are performing very well. These investments are further described in the news releases dated July, 8, 2021 and March 10, 2022.

VSAI is currently marketing a placement based on a substantially higher valuation than the one used when we participated earlier this year (at the time valuation was USD$20 million) as they have advanced their development accordingly.

The Company earned a dividend of approx. EUR 97k compared to the EUR 100k paid in cash purchase consideration the year prior from E&E CRO.

The Company will provide more in depth information, especially on acquisition targets for 2023, after the closing of the proposed financing.

About Principal Technologies Inc.

Principal Technologies Inc. (TSXV: PTEC.P), is building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential, that have achieved regional success. Principal Technologies will also focus on companies that have IP capable of enhancing medical treatment quality and efficiency, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. In addition to providing growth capital, the company also aims to support the growth of its portfolio with the expertise of its management team, board, and advisers. 
Learn more: https://principal-technologies.com/


Jerry Trent, Chief Executive Officer
Principal Technologies Inc.

Cautionary Note Regarding Forward-Looking Information

This news release contains statements which constitute "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"), including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding: (a) expectations regarding whether the Transaction will be consummated including whether the conditions to the consummation of the Transaction; (b) the timing for completing the Transaction, if at all, and the conditions to such transaction; and (c) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the resulting issuer. Among the key factors that could cause real results to differ materially from those projected in the forward-looking statements are the following the ability to consummate the Transaction; the ability to obtain requisite regulatory and shareholder approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and regulations both locally and in foreign jurisdictions; compliance with extensive government regulation; the risks and uncertainties associated with foreign markets; and the diversion of management time on the Transaction. These forward-looking statements may be affected by risks and uncertainties in the business of E&E, the Company and general market conditions, including COVID-19.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, real results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause real results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. E&E and the Company do not intend, and do not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.

Completion of the Transaction is subject to a number of conditions, including but not limited to TSXV acceptance. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the filing statement prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Principal Technologies Inc.

For further information: Investor inquiries, please contact: [email protected]

Mon, 28 Nov 2022 23:03:00 -0600 en text/html https://www.newswire.ca/news-releases/principal-technologies-corporate-update-834505545.html
Killexams : Marias Technology is Hired by Security Mutual Insurance Company

Marias Technology

Marias will assist with testing Security Mutual’s new policy administration system

COVINGTON, Ohio, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Marias Technology, a provider of software testing and implementation services to the insurance industry, has been contracted by Security Mutual Insurance Company, headquartered in Ithaca, New York, to assist with testing the company’s new policy administration system.

“Marias comes to us with extensive experience in insurance system testing, and it shows,” said Lauren Belfiore, Director of Information Systems for Security Mutual. “They were able to jump in and provide value from day one. We’re grateful to Chris Haines and his team for their expertise and their support.”

Under the terms of the agreement, Marias will test Security Mutual’s new system for completeness and accuracy, providing business analysis, quality assurance testing, and user acceptance testing.

“Lauren and her team have been great to work with,” said R. Christopher “Chris” Haines, President and CEO of Marias. “They recognized our level of experience, that we knew their challenges, and that we had the expertise to contribute right from the start. We look forward to being a part of Security Mutual’s success.”

About Marias Technology
Marias Technology, headquartered in Covington, Ohio, a privately held company, offers insurance technology services to property/casualty insurance companies. Services range from system testing and configuration, to defining specifications and defect analysis and investigation. For more information, please visit www.mariastechnology.com, email info@mariastechnology.com, or call 866-611-2212.

About Security Mutual Insurance Company
Starting out as a small county cooperative with $1,273 in premiums, today Security Mutual Insurance Company writes over $45 million in premiums. With over $135 million in assets; over $81 million of policyholder surplus, they provide Property and Casualty Insurance for Home and Business. Security Mutual is represented by a network of more than 400 independent agents throughout New York State. For more information, please visit www.securitymutual.com.

Media Contact:
JoAnna Bennett

Mon, 28 Nov 2022 23:31:00 -0600 en-CA text/html https://ca.sports.yahoo.com/news/marias-technology-hired-security-mutual-133200830.html
Killexams : Outlook on the Biomedical and ICT Convergence Global Market to 2027 - by Technology, Solution and Region

Company Logo

Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2022 - 2027" report has been added to ResearchAndMarkets.com's offering.

This report evaluates the market for convergence between the Information and Communications Technology (ICT) industry and biomedical science and technologies. The report evaluates the latter and analyzes the former in terms of ICT innovation such as connected medical devices.

In addition to forecasts for IoT-connected healthcare devices (standalone, wearable, and implantable), the report also assesses the outlook from 2022 to 2027 for various biomedical products, services, and solutions poised to benefit from various IT and telecom technologies.

Select Report Findings:

  • The biomedical ICT market is expected to reach $73 billion USD by 2027

  • North America will lead the biomedical ICT market during the forecasted period

  • The hardware technology will represent over 52% of the biomedical ICT market by 2027

  • Diagnostic and research will be the prime application area within the biomedical ICT market

  • Biomedical and ICT convergence is the foundation for the preponderance of biomedical technology

The field of biomedicine is concerned with the application of various natural science disciplines for the development of knowledge, interventions, and/or technologies for use in healthcare. The Information and Communications Technology (ICT) sector focuses on telecommunications, computing, and the integration of both.

The convergence of biomedical and ICT represents a high opportunity area for both healthcare and ICT industries. In addition to seeking cures to disease and ailment prevention, combined biomedical and ICT solutions will lead to improved treatment efficacy as well as overall improvements in healthcare service delivery efficiency and effectiveness.

With healthcare costs growing much faster than the general inflation rate, it is of the utmost importance to simultaneously seek improved treatment while continuously driving down business costs. These costs include ongoing operational expenditures as well as expensive R&D such as drug discovery and other pharmaceutical-related areas such as vaccine development that takes into account precision medicine practices.

Various ICT tools may be employed such as IoT-enabled monitoring to determine the effectiveness of medical procedures, which can be especially important when administering new and unproven healthcare modalities. One specific example is the administration of vaccines, which is believed to potentially cause harm to a subset of the population based on epigenetics, which is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.

This is believed to be an area in which a healthcare modality (in this example, vaccines) is designed with one intent (to inoculate one to prevent the onset of disease), but may actually trigger unintended consequences such as causing harm based on an individual's unique gene expression.

One of the fastest-growing areas for ICT in healthcare is the use of wireless access by IP-enabled, handheld digital devices. Wearables and implantable technology hold the promise of a level of monitoring and healthcare administration that is unprecedented in the history of health science. Ranging from treatment administration to clinical decision support, connected devices are a rapidly evolving tool for the advancement of healthcare practices.

These same tools may be used for both reactive and proactive medical modalities such as insulin modification and vaccine optimization respectively. The convergence of ICT and biomedicine is therefore anticipated to lead to both improved economics (lower costs and improved revenues through the identification of new healthcare treatments) as well as Strengthen overall public health.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Biomedical and ICT Technologies and Solutions
3.1 Technology Analysis
3.1.1 Biomedical Diagnostics Devices Electrochemical Test Strips Integrated Cartridges Lateral Flow Assays Molecular Diagnostics
3.1.2 Bionanotechnology
3.1.3 Temperature Sensors
3.1.4 Refrigerators and Freezers
3.1.5 Metal Equipment
3.1.6 Software Technology and ICT Services
3.2 Biomedical and ICT Application Analysis
3.2.1 Diagnostics and Research Solution
3.2.2 Tissue Engineering and Regeneration
3.2.3 Fermentation
3.2.4 Cell Based Assay
3.2.5 PCR Technology
3.2.6 Chromatography
3.2.7 Additive Metal Solution
3.3 Cloning and Somatic Cell Nuclear Transfer
3.4 Industry Specific Uses
3.4.1 Medical, Pharmaceutical, and Health
3.4.2 Food and Agriculture
3.4.3 Natural Resources and Environment
3.4.4 Industrial Processing
3.4.5 Bioinformatics
3.5 Cloud Deployment and IT Infrastructure Management

4. Company Analysis
4.1 Abbott Laboratories
4.2 Amgen Inc.
4.3 Analog Devices
4.4 AstraZeneca
4.5 Biogen
4.6 Bio-Rad Laboratories
4.7 Biodirection
4.8 BioTelemetry
4.9 Carpenter Technology
4.10 Celgene Corporation
4.11 Dentsply Sirona
4.12 First Sensor
4.13 GE Healthcare
4.14 Gilead Sciences
4.15 Haier Biomedical
4.16 Helmer Scientific
4.17 Hoffman-La Roche Ltd.
4.18 Honeywell
4.19 Johnson & Johnson
4.20 Lonza Group
4.21 Medtronic
4.22 Merck & Co
4.23 Nonin Medical
4.24 Novartis AG
4.25 Novo Nordisk
4.26 NXP Semiconductor
4.27 Panasonic
4.28 Pfizer Inc.
4.29 Sanofi Aventis
4.30 Smiths Medical Inc.
4.31 STMicroelectronics
4.32 TE Connectivity
4.33 Texas Instruments
4.34 Thermo Fisher
4.35 Wright Medical Group
4.36 Zimmer Biomet

5. Biomedical ICT Market Analysis and Forecast 2022 - 2027
5.1 Global Biomedical ICT Market 2022 - 2027
5.1.1 Aggregate Market 2022 - 2027
5.1.2 Market by Technology 2022 - 2027 Market by Hardware 2022 - 2027 Market by Diagnostic Device 2022 - 2027 Market by Temperature Sensor 2022 - 2027 Market by Refrigerators and Freezers 2022 - 2027 Market by Metal Equipment 2022 - 2027 Market by Software 2022 - 2027 Market by Service 2022 - 2027
5.1.3 Market by Solution 2022 - 2027 Market by Diagnostics and Research Solution 2022 - 2027 Market by Biomedical Metal Solution 2022 - 2027
5.1.4 Market by Industry Vertical 2022 - 2027
5.1.5 Market by Cloud Deployment 2022 - 2027
5.2 Regional Biomedical ICT Market 2022 - 2027
5.2.1 Market by Region 2022 - 2027
5.2.2 North America Market Forecast 2022 - 2027
5.2.3 Europe Market Forecast 2022 - 2027
5.2.4 APAC Market Forecast 2022 - 2027
5.2.5 Latin America Market Forecast 2022 - 2027
5.2.6 Middle East and Africa Market Forecast 2022 - 2027

6. Conclusions and Recommendations

7. Appendix: Connected Medical Device Market Analysis and Forecasts

For more information about this report visit https://www.researchandmarkets.com/r/8v5qw8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Tue, 29 Nov 2022 22:38:00 -0600 en-CA text/html https://ca.sports.yahoo.com/news/outlook-biomedical-ict-convergence-global-123800723.html
Killexams : IBEX Technologies Full Year 2022 Earnings: EPS: CA$0.067 (vs CA$0.031 in FY 2021)

Key Financial Results

  • Revenue: CA$7.89m (up 49% from FY 2021).

  • Net income: CA$1.67m (up 120% from FY 2021).

  • Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue.

  • EPS: CA$0.067 (up from CA$0.031 in FY 2021).


All figures shown in the chart above are for the trailing 12 month (TTM) period

IBEX Technologies shares are down 15% from a week ago.

Risk Analysis

Be aware that IBEX Technologies is showing 2 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Wed, 16 Nov 2022 21:16:00 -0600 en-US text/html https://finance.yahoo.com/news/ibex-technologies-full-2022-earnings-110137390.html

VANCOUVER, BC, Nov. 29, 2022 /CNW/ - Atmofizer Technologies Inc. (the "Company" or "Atmofizer") (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) is pleased to announce its exact progress in developing its technology for the HVAC market and its financial results for the quarter ended September 30, 2022. All amounts are expressed in United States dollars unless otherwise noted.


The Company continues to transition the business to its most valuable addressable market to integrate the agglomeration technology into existing forced air systems. The Company is ready to focus on the third objective of our strategic plan: 1 - Prove it, 2 - Protect it, 3 - Promote it.


The Company has been working closely with an HVAC service provider in the United States. The Company has validated the product market fit and helped to develop the final production design which can be installed in less than 15 minutes by any HVAC service technician and sell for less than other similar accessories in the market. The Company has completed testing on the HVAC solution with almost immediate agglomeration at air speeds consistent or superior to most HVAC applications, meaningful improvement of filter performance and Strengthen HVAC performance. The last phase of comprehensive third-party laboratory tests to independently certify the results of this new product range is scheduled for January 2023. The design can be easily adapted to expand beyond the residential HVAC market to service commercial, industrial and agricultural applications.


The Company successfully received its second US patent, its agglomeration technology for integrated and HVAC applications. On August 23, 2022, the Company announced that the USPTO issued a Notice of Allowance for new claims related to the Company's air and water purification technology. This was followed by a formal patent issuance on October 25, 2022. (U.S. Patent No. 11,478,742). The allowed patent application, titled, "Ultra-Fine Particle Aggregation, Neutralization and Filtration" (US Patent Application No. 11,291,939) provides broad protection for important aspects of Atmofizer's air purification technology. The Notice of Allowance from the USPTO is directed to a new design that delivers ultra-fine particle agglomeration and nanoparticle reduction performance in larger air ducts with faster-moving air, using less parts.


The HVAC solution has been designed to scale to other HVAC applications with an asset light strategy that will target existing HVAC suppliers and manufacturers with existing distribution and scale. The Company will look to partner to execute its asset light, technology first approach to license its patented technology for high margin licensing opportunities. The Company is in the final stages of distribution discussions with a partner in the United States to launch its HVAC solution, to be announced in due course.


On August 23, 2022, the Company announced that the USPTO issued a Notice of Allowance for new claims related to the Company's air and water purification technology. The allowed patent application, titled, "Ultra-Fine Particle Aggregation, Neutralization and Filtration" (US Patent Application No. 11,291,939) provides broad protection for important aspects of Atmofizer's air purification technology. The exact Notice of Allowance from the USPTO is directed to a new design that delivers ultra-fine particle agglomeration and nanoparticle reduction performance in larger air ducts with faster-moving air, using less parts. The Company plans to market this patent to be licensed by air purification device manufacturers, HVAC suppliers and service companies. This was followed by a formal patent issuance on October 25, 2022. (U.S. Patent No. 11,478,742). The allowed patent application, titled, "Ultra-Fine Particle Aggregation, Neutralization and Filtration" (US Patent Application No. 11,291,939) provides broad protection for important aspects of Atmofizer's air purification technology.

On August 25, 2022, the Company announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction ( > 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020).

Atmofizer ONE Performance Update

Atmofizer Efficacy Claims:

  • 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria]
  • 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria]
  • 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]

Atmofizer SARS-CoV-2 Specific Efficacy Claims

  • Atmofizer reduces airborne SARS-CoV-2
  • Atmofizer destroys over 99.99% SARS-CoV-2 without a filter
  • Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes

These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The FDA has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.

As of the nine months ended September 30, 2022, the Company had issued 46,791,500 common shares in the authorized share structure of the Company ("Common Shares") with gross proceeds of C$2,338,580 under the "at-the-market" equity distribution program pursuant to a prospectus supplement dated February 26, 2022 (the "ATM Program").


For the three months ended September 30, 2022, the Company generated nil revenue compared to $23,585 in revenue and a gross profit of $6,810 (28.87%) during the three months ended September 30, 2021.

Our initial launch of the portable device application which leveraged our patented agglomeration technology to bunch together small particles and enhance the impact of industry ultra-violet technology to neutralize viruses and bacteria by absorbing more heat. Despite the performance results achieved by the technology to deliver and the increased demand related to the COVID-19 pandemic, the Company was faced with supply chain disruptions that had severe impacts on competitive market pricing where traditional lower cost devices, regulatory marketing claim uncertainty and lack of consumer knowledge of published results in the sector that severely impacted revenues. The two core device distributors were affected by the previously reported supply chain disruptions highlighted in our second quarter MD&A which affected their ability to convert their sales pipeline into revenue. Demand for air purifier devices has softened since the decline in COVID-19. In light of the poor sales performance from the Company's main distributor, USA Tech Direct, the Company and USA Tech Direct have decided to phase out their distribution relationship. 

In addition, the Company was successful in securing an additional US patent on its agglomeration technology within an HVAC application. On August 23, 2022, the Company announced that the USPTO issued a Notice of Allowance for new claims related to the Company's air and water purification technology. This was followed by a formal patent issuance on October 25, 2022. (U.S. Patent No. 11,478,742). The allowed patent application, titled, "Ultra-Fine Particle Aggregation, Neutralization and Filtration" (US Patent Application No. 11,291,939) provides broad protection for important aspects of Atmofizer's air purification technology. The exact Notice of Allowance from the USPTO is directed to a new design that delivers ultra-fine particle agglomeration and nanoparticle reduction performance in larger air ducts with faster-moving air, using less parts. The Company plans to market this patent to be licensed by air purification device manufacturers, HVAC suppliers and service companies. The Company expects that the application of its agglomeration technology in the HVAC market is a larger market opportunity than the air purifier market in the United States. Products would be available for this market opportunity in the first quarter of 2023.

During the nine months ended September 30, 2022, the Company generated revenue of $210,000 with a gross profit of $60,293 (28.71%) compared to $76,585 with a gross profit of $27,298 (35.64%) during the nine months ended September 30, 2021. 

The Company incurred $4.5 million in expenses during the three months ended September 30, 2022, compared to $2.1 million during the three months ended September 30, 2021. The increase of $2.4 million increase in expenses was driven primarily by an increase in share-based payments of $2.5 million, an increase in amortization of $0.2 million and impairments of inventories and receivables of $0.4 million and an increase in salaries and wages of $0.2 million. There were significant decreases over the previous quarter in management fees ($0.4 million), consulting fees ($0.3 million) and professional fees ($0.2 million). The Company has focused on reducing operating expenses and excluding amortization expenses, impairments of inventories and receivables and share-based payments, operating expenses were reduced by $0.8 million during the quarter ended September 30, 2022. In addition, during the three months ended September 30, 2022, the Company recognized an impairment of receivables of $0.1 million and impairment of inventories of $0.3 million. No such impairment was recognized in previous year. 

The Company incurred $16.1 million in expenses during the nine months ended September 30, 2022, compared to $5.9 million during the nine months ended September 30, 2021. The increase of $10.2 million in expenses was driven primarily by share based payments of $9.3 million and $1.6 million in sales and marketing expense of which $1 million was paid by issuing the Common Shares. There were significant decreases over the previous year in consulting fees ($1.1 million), management fees ($0.9 million) and research and development expenses ($0.5 million). The Company has focused on reducing operating expenses and excluding amortization expenses, impairments of inventories and receivables and share-based payments, operating expenses were reduced by $1.4 million for the nine months ended September 30, 2022.

During the three months ended September 30, 2022, the Company recorded net loss of $4.6 million compared to a net loss of $2.1 million for the three months ended September 30, 2021. The biggest contributors to the increase in the net loss of $2.5 million were share-based payments of $2.5 million, salaries and wages of $0.2 million, impairment charges of $0.4 million and amortization of $0.2 million, which were offset by a decrease in management fees ($0.4 million), consulting fees ($0.3 million) and professional fees ($0.2 million).

During the nine months ended September 30, 2022, the Company recorded net loss of $16.1 million compared to a net loss of $5.9 million for the nine months ended September 30, 2021. The biggest contributors to the increase in the net loss of $10.2 million were share-based payments of $9.0 million, sales and marketing of $1.3 million, salaries and wages of $0.8 million, impairment charges of $0.9 million and amortization of $0.7 million, which were offset by a decrease in management fees ($0.9 million), consulting fees ($1.1 million) and research and development ($0.5 million).

"The Company achieved a number of important technology development milestones during the second quarter of 2022. Our science team continued to make significant advancements to prove and productize our technology to achieve our ultimate goal of delivering cleaner air, energy savings and improved efficiency during the quarter. We are doing this by expanding beyond our appliance business and into the multi-billion dollar HVAC industry. We recently received a Notice of Allowance for new claims related to the Company's air purification technology from the USPTO. The exact Notice of Allowance from the USPTO is directed to a new design that delivers ultra-fine particle agglomeration and nanoparticle reduction performance in larger air ducts with faster-moving air, using less parts," said Atmofizer CEO, Olivier Center. "The Company plans to market this patent to be licensed by air purification device manufacturers, HVAC suppliers and service companies. Our first priority is to leverage our strong relationships with HVAC distribution partners to commercialize our nano particle agglomeration technology through licensing. With respect to our appliance business, we experienced head winds from both supply chain related issues as well as regulatory issues. We see ourselves now in a better position to work with our distributors under the FDA's Air Purifier Policy and deliver appliance sales as well as having more appliance inventory on hand to sell through. We continue to follow our asset light objective of developing new clean technology and licensing or partnering with industry leaders to scale faster and capital efficiently."


On November 4, 2022, the Company sold a property based in Mississauga, Ontario (the "Mississauga Property") for C$575,000 to a real estate developer (the "Buyer"). The Company received $150,000 immediately upon closing and agreed to provide the Buyer a six-month 7.5% first ranking vendor-take back mortgage against the Mississauga Property for the balance of the proceeds of $425,000. The mortgage matures on May 1, 2023. The Mississauga Property was a non-core asset of the Company, which two of its subsidiaries acquired title to pursuant to a legacy option agreement for nil consideration immediately prior to the sale transaction.

About Atmofizer Technologies Inc.

Atmofizer's consumer and industrial solutions are based on its patent-protected and patent pending technology for ultrafine particle agglomeration and neutralization. This capability creates a revolutionary and more efficient method for addressing the wide range of dangerous nano-scale particles, viruses and bacteria that are too small to be effectively managed by conventional HEPA filters and ultraviolet lights. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while lowering customers' operational costs.

Atmofizing air refers to the process of using ultrasonic acoustic waves to agglomerate (cluster together) small particles into a larger target that is then radiated by ultraviolet light to neutralize their harmful properties, making the air you breath less hazardous to your health. Using units that atmofize air in tandem with high efficiency particulate air ("HEPA") filters can make the HEPA filters work more efficiently, enable the use of a less-powerful filter and result in a cleaner and longer-lasting filter that reduces operating costs and is less of a health hazard to clean or replace.

Atmofizer is patent-pending and patent-protected sole source of technology to atmofize air and is applying its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that integrate Atmofizer technology into their own products under license. Atmofizer's owned and licensed product lines include wearable, portable and mobile use for personal air treatment, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential applications.

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the business and strategic plans of the Company.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which provide rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause real results to differ materially from the forward-looking information in this press release including, without limitation: the Company's ability to comply with all applicable laws and governmental regulations relating to its commercial products; the ability of the Company to protect its intellectual property; impacts to the business and operations of the Company due to the COVID-19 pandemic; the conflict in eastern Europe; having only a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent real events and such forward-looking information, except as required by applicable law.

SOURCE Atmofizer Technologies Inc.

For further information: For additional information on the Company, please contact: Olivier Centner, Chief Executive Officer, Telephone: 305-902-1858, Email: [email protected]; For Media Inquiries and Investor Relations, please contact: Email: [email protected]

Tue, 29 Nov 2022 08:32:00 -0600 en text/html https://www.newswire.ca/news-releases/atmofizer-technologies-inc-announces-hvac-market-development-and-third-quarter-2022-financial-results-851016517.html
CAT-200 exam dump and training guide direct download
Training Exams List